Syntr Health Technologies is honored to be part of this year's Clinton Global Initiative University Conference and Commitment Challenge at Northeastern University. This is a fundraising challenge for student leaders with projects from all around the world and a once-in-a-lifetime opportunity to be with like-minded individuals and grow together as leaders of the future.
WE NEED YOUR HELP TO RAISE MONEY FOR OUR WORTHY CAUSE AS WELL AS TO WIN THIS CHALLENGE!
Diabetes in the U.S. affects about 10% of the population. We all either have a close relative who has diabetes or know someone who is affected by it. Although medication may help keep diabetes under control, the co-morbidities of diabetes can be debilitating. Up to 25% of patients with diabetes will develop a Diabetic Foot Ulcer (DFU) in their lifetime, with a reported 770,000 new cases annually. DFUs are the leading cause of nontraumatic lower-limb amputations, and a staggering 50% of these amputees die within five years after having such surgery.
Current technologies offered for the treatment of DFUs such as bioengineered cell-based skin substitutes (allografts) have unpredictable results and/or are associated with significant cost. Their prices range from $1,700 to upwards of $9,200. Their results have shown poor efficacy, and their application requires multiple steps as well as several visits to the physician for reapplication. There is a pressing need for a better solution.
This project hits very close to home as many of our team members have lost relatives due to DFUs or other diabetes-related complications.
Our team of engineers and scientists have developed a point-of-care therapeutic device that harnesses the wound healing potential of mechanically activated fat-derived stem cells. The therapeutic utilizes a patient's own fat-derived stem cells that, once activated, are then reintroduced into the patient's affected area to induce healing from the inside out. As a point-of-care therapeutic, the potential for graft and stem cell rejection are eliminated since the clinician will inject the patient’s own stem cells immediately following harvesting of the fat tissue with minimal manipulation. Our new therapeutic will provide an affordable, autologous, and same-day treatment solution that can be performed in under an hour, that will result in an overall attenuation of the burden of DFUs and prevention of associated amputations.
The statistics provided by the Center for Disease Control and Prevention (CDC) make a compelling argument for addressing the DFU problem.
● 30 million adults were estimated to have diabetes in 2010
● 100 million adults in the U.S. are projected to have diabetes by 2050
● 25% of diabetics will develop a DFU in their lifetime
● 770,000 new cases of DFU reported annually
● 30% amputation rate after developing a DFU
● 50% of amputees die within five years after surgery
The growing diabetic population and number of associated amputations is overwhelming the healthcare system. With an affordable point-of-care therapeutic, we aim to reduce the number of DFU-related amputations and resulting financial burden on the healthcare system.
We early ask for your generous support of Syntr Health Technologies. Your contribution will help offset the cost of FDA approval and bring the device closer to being commercial-ready. With your help, Syntr Health Technologies will deliver this much-needed therapeutic that will help prevent thousands of amputations and ultimately, SAVE LIVES!